Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly reported Q4 2025 revenue growth of 43% YoY and full-year revenue of $65.2B (+45% YoY), with EPS up 86% to $24.21. 2026 guidance calls for $80–$83B in revenue (+25% YoY at midpoint), driven ...

Eli Lilly (LLY) stock is priced at 38.7 times earnings, compared with 21.5 for the S&P 500. Investors evaluating that valuation should weigh what drives it, especially since the company's priorities ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Olix eases overhang, targets Q4 Korea tech transfer on obesity and eye drugs Overhang risk fades as CPS converts, with Q4 tech transfer tests looming for obesity and macular degeneration programs ...

Novo Nordisk trades at ~11.2x 2027 earnings, a ~26% discount to peer median. Read more on why NVO stock is a Buy and LLY stock is a Hold.